PEREGRINE AND NABTT CONSORTIUM INITIATE BRAIN CANCER TRIAL

Peregrine Pharmaceuticals and the New Approaches to Brain Tumor Therapy (NABTT) Consortium have initiated a clinical trial designed to confirm the dosing, safety and efficacy of a single intratumoral infusion of Cotara in the treatment of glioblastoma multiforme, a common and deadly form of brain cancer.

The National Cancer Institute-approved protocol titled, "An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B (Cotara) for the Treatment of Glioblastoma Multiforme at 1st or 2nd Relapse," will evaluate safety, radiation exposure and efficacy of a single dose of Cotara. The study represents the first part of Peregrine's FDA-approved product registration clinical trial for Cotara.

The trial will enroll patients at four NABTT institutions: Wake Forest University, Emory University, University of Alabama at Birmingham and University of Pennsylvania. Up to 28 patients will be enrolled in the trial.